Capricor Therapeutics prices $150M public offering of 6M shares at $25/sh

CAPRICOR THERAPEUTICS, INC.

Offering 6,000,000 shares at $25.00 per share; expected gross proceeds ~$150M.
Underwriters granted 30-day option to purchase up to 900,000 additional shares.
Net proceeds for product candidate development, manufacturing, working capital, and corporate purposes.
Joint book-running managers: Piper Sandler & Co. and Oppenheimer & Co.; co-manager: H.C. Wainwright & Co.
Offering expected to close on or about December 8, 2025, subject to customary conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.